



CME on Quality Assurance in Haematology Lab 2026

Saturday, 3rd October, 2026

Vivanta, Kolkata

The Indian Society of Haematology and Blood Transfusion (ISHBT) successfully organized the CME on “Quality Assurance in Haematology Lab 2026” on Saturday, 3rd October 2026, at Vivanta, Kolkata. The Continuing Medical Education (CME) programme aimed to emphasize the importance of quality assurance in haematology laboratories, focusing on accuracy, reliability, standardization, and continuous improvement in laboratory practices. The programme provided an academic platform for medical professionals, laboratory specialists, and delegates to enhance their understanding of quality management systems and their role in ensuring dependable laboratory results. The scientific sessions covered key aspects of laboratory quality assurance, including the principles and implementation of a Laboratory Quality Management System (LQMS), quality control practices, standard operating procedures, and strategies to improve the overall quality of haematology laboratory services. The sessions encouraged knowledge-sharing and discussion on practical approaches to addressing laboratory challenges and maintaining high standards of diagnostic accuracy. The CME brought together experts and healthcare professionals to exchange experiences, discuss evolving practices, and highlight the critical role of quality assurance in patient care. The programme reinforced the need for continuous professional development, adherence to quality standards, and the adoption of systematic approaches to laboratory management. Through this academic initiative, ISHBT reaffirmed its commitment to promoting excellence in haematology, strengthening laboratory practices, and supporting the delivery of accurate and reliable diagnostic services across healthcare settings. The CME concluded as a valuable educational initiative, contributing to greater awareness of quality assurance and encouraging the continued pursuit of excellence in haematology laboratory services.

3rd National Post-doctoral Haematology Quiz 2026

East / North-East Zonal Round Quiz

Saturday, 3rd October, 2026

Vivanta, Kolkata

The Indian Society of Haematology and Blood Transfusion (ISHBT) successfully organised the East/North-East Zonal Round of the 3rd National Post-doctoral Haematology Quiz 2026 on Saturday, 3rd October 2026, at Vivanta, Kolkata. The event brought together post-doctoral haematology trainees in an intellectually stimulating academic competition designed to assess and enhance their knowledge, clinical acumen, and understanding of haematological disorders. The quiz provided a valuable platform for young haematologists to demonstrate their expertise, engage in healthy academic competition, and learn from their peers. The zonal round featured challenging questions covering various aspects of haematology, encouraging participants to apply their theoretical knowledge and clinical reasoning. Such academic initiatives play an important role in strengthening postgraduate and post-doctoral training while promoting a spirit of excellence and collaboration among budding specialists. Through this initiative, ISHBT reaffirmed its commitment to advancing haematology education and fostering the professional development of young haematologists across the

country. The National Post-doctoral Haematology Quiz continues to serve as an important educational platform for identifying and nurturing emerging talent in the field. The successful conduct of the East/North-East Zonal Round at Vivanta, Kolkata, reflected ISHBT’s ongoing efforts to promote academic engagement, encourage knowledge-sharing, and uphold high standards of haematology education and clinical practice in India.






67th Annual Conference of
Indian Society of Hematology & Blood Transfusion

HAEMATOCON 2026

Theme: - Advancing Hematology: From Evidence to Clinical Excellence

12th - 15th NOV, 2026 | Ahmedabad, India

Register Now - www.haematocon2026.in



Clinical Hematology and Hemato-Oncology

Diagnosis, Management, and Advances

- Provides case-based discussion, and algorithm for approach to diagnosis/ treatment in each chapter
- Discusses high-end laboratory tests in diagnosis/ risk stratification of hematological malignancy
- Includes separate chapters on gene therapy, and car-T cell therapy

Book Link:
<https://link.springer.com/book/10.1007/978-981-92-1167-8>



Masterclass of ISHBT

51st Masterclass of ISHBT

Topic: YTD
Speaker: YTD
Date: Wednesday, 28th October, 2026
Time: 07:00 P.M. IST

<https://>

Indian Journal of Haematology & Blood Transfusion (IJHBT)
Publishing model - Hybrid
Volume: 42, Issue: 5, Sep, 26
90 articles in this issue



Click below link to read or download
<https://link.springer.com/journal/12288/volumes-and-issues/42-4>



Newsletter




The Hematology India

VOLUME 3 - ISSUE 2
August 15, 2026

Click below link to read or download

<https://ishbtish.com/?p=web/newslettervolume>

Guideline By Indian College of Hematology (ICH)



Available On
Jaypee Brothers Medical Publishers,
Amazon & AIBH
<https://ishbtish.com/ich/guidelines.html>

What's new in Haematology in Oct, 2026

For October 2026, the most useful haematology updates to follow are advances in malignant haematology, cellular therapies, benign blood disorders, laboratory diagnostics, and clinical guidelines.

The key areas to review are:

Leukaemia and lymphoma:

New targeted treatments, immunotherapies, and clinical trial results.

Multiple myeloma:

CAR-T cell therapy, bispecific antibodies, and strategies for relapsed or refractory disease.

Benign haematology:

Advances in haemophilia, thalassaemia, sickle cell disease, and immune cytopenias.

Transfusion medicine:

Blood safety, patient blood management, and transfusion compatibility.

Laboratory haematology:

Quality assurance, molecular diagnostics, measurable residual disease (MRD), and digital morphology.

Chronic lymphocytic leukaemia (CLL): New treatment option

The US FDA approved pirtobrutinib for previously untreated adults with CLL or small lymphocytic lymphoma (SLL) without a known 17p deletion on 2 October 2026. This is an important development in the evolving treatment landscape for CLL.

Source: FDA haematologic malignancy approvals

Iron deficiency: Updated diagnostic guidance

The American Society of Hematology (ASH) highlighted new guidance on diagnosing iron deficiency across different populations, including children, pregnant individuals, menstruating adults and people with inflammation. The update is relevant to interpreting iron studies and reducing missed diagnoses.

Source: ASH Newsroom

Multiple myeloma: New combination therapy

The US FDA granted accelerated approval to iberdomide in combination with daratumumab and dexamethasone for certain adults with multiple myeloma after at least one prior line of treatment that included a proteasome inhibitor and an immunomodulatory agent. This adds another option for selected previously treated patients.

Source: FDA drug approval notifications

Stem cell transplantation: Advances in immune-cell therapy

The FDA approved Tregzi, an allogeneic regulatory T-cell-based therapy used with matched-donor haematopoietic stem cell transplantation in adults with haematological malignancies. Its indication includes improving chronic graft-versus-host disease-free survival.

Source: FDA approval details